SSA
RAPT

Schonfeld Strategic Advisors’s RAPT Therapeutics RAPT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,500
Closed -$3.67M – 2864
2021
Q4 		$3.67M Buy
+12,500
New +$3.34M 0.03% 542

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Schonfeld Strategic Advisors's RAPT Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 13,830 shares — an estimated $2.75M sold.

Schonfeld Strategic Advisors first reported a position in RAPT in Q2 2020 and held it in 14 quarters. The position peaked at $8.04M in Q3 2020. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • Schonfeld Strategic Advisors reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 13,830 RAPT Therapeutics shares in Q1 2024, an estimated $2.75M.
  • Schonfeld Strategic Advisors first reported a position in RAPT Therapeutics in Q2 2020 and held it in 14 quarters.
  • Schonfeld Strategic Advisors's RAPT Therapeutics position peaked at $8.04M in Q3 2020.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.